Comparison of Microbiota in Patients Treated by Surgery or Chemotherapy by 16S rRNA Sequencing Reveals Potential Biomarkers for Colorectal Cancer TherapyOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study used next generation sequencing-based 16S rRNA gene analysis to characterize the gut microbiota composition in colorectal cancer (CRC) patients following anti-cancer treatment. The researchers specifically compared microbial communities across patients treated with surgery versus those treated with chemotherapy. The goal was to identify how these treatments reshape the microbiome and whether specific bacteria are linked to chemoresistance during CRC therapy.
Who was studied?
The analysis was based on a total of 69 fecal samples collected across four clinical groups. These groups included healthy individuals, untreated CRC patients, CRC patients treated with surgery, and CRC patients treated with chemotherapy. The abstract does not provide further demographic details such as age or sex distribution.
What were the most important findings?
Surgery was found to greatly reduce bacterial diversity in the gut microbiota of CRC patients. Fusobacterium nucleatum was shown to confer chemoresistance during CRC therapy. Additionally, certain bacterial strains or genera, including the genus Sutterella and the species Veillonella dispar, were specifically associated with CRC patients treated with chemotherapeutic cocktails, suggesting a potential relationship with chemoresistance.
What are the greatest implications of this study?
These findings suggest that specific gut bacteria, such as Fusobacterium nucleatum, Sutterella, and Veillonella dispar, could serve as candidate biomarkers for monitoring or predicting chemoresistance in CRC patients. The marked loss of bacterial diversity after surgery also points to a treatment-related microbiome disruption that may warrant clinical attention. Together, these results support further investigation into the gut microbiota as a tool for guiding or evaluating CRC therapy.